DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom (DXCM) to $100 from $90 and keeps an Overweight rating on the shares. The firm notes the company reported full Q4 results, ...

Pre-earnings options volume in DexCom (DXCM) is 2.4x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.7%, or $5.59, after results are released.

Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have earned an average rating of “Moderate Buy” from the twenty brokerages that are covering the company, MarketBeat Ratings reports. Four ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

DexCom (NASDAQ:DXCM – Get Free Report) had its price objective increased by research analysts at Barclays from $90.00 to $93.00 in a report issued on Monday,Benzinga reports. The brokerage presently ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $85 from $100 but keeps an Outperform rating on the shares. The market misunderstood the conservative initial 2026 guide, which likely ...

The average one-year price target for DexCom (XTRA:DC4) has been revised to 77,50 € / share. This is a decrease of 12.36% from the prior estimate of 88,43 € dated November 9, 2025. The price target is ...

) has been revised to $88.30 / share. This is a decrease of 13.54% from the prior estimate of $102.13 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...